Cancer drug licensed by GSK from China posts promising trial results
- Posted on April 12, 2026
- By Financial Times
- 10 Views
Cancer drug licensed by GSK from China posts promising trial results
Mo-Rez, developed by Hansoh Pharma, is a next-generation treatment for ovarian and endometrial cancer
